Please login to the form below

Not currently logged in
Email:
Password:

Astellas signs CNS deal with BioFocus

Astellas Pharma is to focus on central nervous system (CNS) disorders with the help of BioFocus

Astellas Pharma has signed a collaboration agreement with BioFocus focused on discovering novel targets in the field of central nervous system disorders.  

Under the agreement, BioFocus will utilise its SilenceSelect target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration.  

Dr Chris Newton, managing director of BioFocus, said: "We are delighted to support Astellas Pharma in its research. Our target discovery offering allows clients to access a unique platform providing rapid identification of novel targets through a proven technology."

12th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

Webinar: Usability and UX: You’ve been asked to test...What next?
Thursday 27th June 2019 10am EDT / 3pm BST / 4pm CEST...
Event: EphMRA Annual Conference
We're sponsoring, exhibiting and presenting three papers at this year’s EphMRA Annual Conference in Warsaw, Poland....
Research Partnership and Janssen awarded runner-up in MR Excellence Awards
...

Infographics